At the same time that we're seeing downsizing of in-house R&D, AstraZeneca announced its intention to follow an outsourcing model. Sanofi-Aventis yesterday announced a new research partnership agreement with Aviesan as reported in Pharmaceutical Business Review. The goal is to increase knowledge in life science and healthcare in disease areas like ageing, immuno-inflammatory diseases, infectious disease and regenerative medicine. Aviesan is comprised of the CEA, CNRS, INRA, INRIA, Inserm, Institut Pasteur, IRD, conference of university presidents and conference of regional and university hospital CEOs.
Similarly, Genentech announced today a $13 M research agreement with the Univeristy of California at San Francisco as reported in Fierce Biotech. This agreement will address new therapies for neurodegenerative diseases. A Univeristy spokesman said this agreement is transformative from the university's perspective as it is a true collaboration to generate drug candidates.
Clearly, we have an industry in transition. New models to replace existing R&D models are being explored and will continue to be explored until a greater rate of product success is achieved or we all implode.
Posted by Bruce Lehr Feb 20, 2010